Psychosis, Schizophrenia, Sensitisation
Conditions
Keywords
Dopamine, Amphetamine, Positron Emission Tomography, Magnetic Resonance Imaging, Schizophrenia, Psychosis, [18F]FDOPA, [11C]-(+)-PHNO
Brief summary
Patients with schizophrenia show enhanced dopamine synthesis capacity and release, an effect that can be evoked in healthy subjects by repeated amphetamine administration. Therefore for the first time the relationship between dopamine synthesis and release will be studied in healthy subjects before and after amphetamine sensitization in order to better understand adaptive mechanisms of the dopamine system.
Detailed description
Positron emission tomography (PET) studies have consistently shown increased brain dopamine (DA) synthesis and enhanced d-amphetamine-induced DA release in patients with schizophrenia. Repeated administration of d-amphetamine leads to an increased subjective and behavioral drug-response. This effect, termed sensitization, is paralleled by an increase in dopamine release to levels akin to those observed in schizophrenia. Schizophrenia thus goes along with a state of 'natural sensitization' towards amphetamines. However, while it is known that DA synthesis and release are both enhanced in schizophrenia, it is unknown whether sensitization changes indices of presynaptic DA synthesis in the striatum of healthy subjects. Thus, for the first time, this project will study the effects of repeated d-amphetamine on uptake of the DA precursor \[18F\]FDOPA and on d-amphetamine-induced changes in binding of the D2/3 receptor agonist radioligand \[11C\]-(+)PHNO in a within-subject design. Before and after amphetamine sensitization by repeated intermittent administration subjects will receive an \[18F\]FDOPA and and a \[11C\]-(+)PHNO PET scan. For the investigation of the influence of functional and structural cortical properties on dopamine synthesis and release, functional and structural magnet resonance imaging will be performed before and after sensitization.
Interventions
DRUGDextroamphetamine Sulfate
Repeated oral administration of dexamphetamine 0.4mg/KG bodyweight four times.
Sponsors
Medical University of Vienna
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Males and females aged 18-65, in good general health based on history and physical examination * Psychiatrically healthy as determined by the Mini-International Neuropsychiatric Interview (M.I.N.I.PLUS) (94)) * No relevant abnormalities in laboratory screening including thyroid function tests, blood cell count, serum electrolytes, liver and kidney function, and urinalysis * No clinically relevant findings in electrocardiography (ECG) * No clinically relevant findings in vital signs (blood pressure and pulse) * No regular use of illegal drugs or alcohol abuse based on declared history and confirmed by urine drug screening * No history of repeated AMPH (AMPH), cocaine or other stimulant drug use
Exclusion criteria
* Evidence of present psychiatric or neurological illness according to M.I.N.I.-Plus (any personal or first-degree relative history of: schizophrenia, bipolar disorder, attention-deficit/hyperactivity disorder, and substance dependence) * Recreational use of psychostimulant drugs in the past two years; lifetime use of psychostimulants exceeding five exposures * Medically significant biochemical or hematological abnormality on screening laboratory studies * Women of childbearing potential: Current pregnancy or breast-feeding * Clinically relevant abnormalities in the electro-cardiogram (ECG) * History of myocardial infarction or angina pectoris * Positive urine drug screen within one week prior to PET study day * Presence of ferromagnetic metal in the body or heart pacemaker * Claustrophobia * Any history of arterial hypertension or paroxysmal hypertensive states * Established diagnosis of advanced arteriosclerosis * Established diagnosis of hyperthyroidism * History of hypersensitivity to sympathomimetics * History of head trauma resulting in loss of consciousness that required medical intervention * Lifetime history of substance dependence (except nicotine) * If participation in this study would exceed the annual radiation dose limits (30 mSv) for human subjects * Subjects currently participating in research studies * Suicidal ideation or likelihood of a suicide or homicide attempt
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| [18F]FDOPA Ki values | Baseline and 2 weeks after amphetamine sensitization, Week 1 and Week 4 | Relative change in regional \[18F\]FDOPA Ki values after AMPH sensitization |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Subjective ratings of amphetamine effects (Drug Effects Questionnaire) | Baseline, after i.v. amphetamine during PHNO PET, on each of the two sensitization visits and 2 weeks after amphetamine sensitization during PHNO PET scanning over the course of 4 weeks. Time points: Week 1 Week 2 Week 4 | Subjective ratings will be assessed via questionnaire (Drug Effects Questionnaire) four times throughout the study. |
| Subjective ratings of amphetamine effects (Subjective States Questionnaire) | Baseline, after i.v. amphetamine during PHNO PET, on each of the two sensitization visits and 2 weeks after amphetamine sensitization during PHNO PET scanning over the course of 4 weeks. Time points: Week 1 Week 2 Week 4 | Subjective ratings will be assessed via questionnaire (Subjective States Questionnaire) four times throughout the study. |
| Cognitive measures | At baseline, on each of the two sensitization visits after amphetamine administration and 2 weeks after amphetamine sensitization before FDOPA scanning, total timeframe 4 weeks, Time points: Week 1 Week 2 Week 4 | Working memory, reward processing and impulsivity will be assessed via a computerized test battery four times throughout the study |
| Impulsiveness | Baseline, Week 1 | The personality traits impulsiveness will be assessed once during study participation by the questionnaire Barrat Impulsiveness Scale (BIS). |
| Personality-related markers | Baseline, Week 1 | Personality traits like novelty seeking will be assessed once during study participation using the Temperament and Character Inventory (TCI). |
| [11C]-(+)-PHNO BPND values | Baseline and 2 weeks after amphetamine sensitization, Week 1 and Week 4 | Relative change in regional \[11C\]-(+)-PHNO BPND values after AMPH administration before and after sensitization |
| Salivary cortisol | Salivary cortisol will be assessed each time amphetamine is administered: At baseline and 30, 60, 90, 145 and 210 minutes after i.v. or oral amphetamine administration. | Salivary cortisol will be assessed using Salivettes ®. |
| Fractional anisotropy (diffusion-weighted tensor imaging) of white matter | Before and after amphetamine sensitization, Week 1, Week 5 | Fractional anisotropy of white matter will be measured by means of magnet resonance imaging. |
| Gray matter volume | Before and after amphetamine sensitization, Week 1, Week 5 | Gray matter volume will be measured by means of magnet resonance imaging. T1 and PD sequences will be recorded. |
| Functional connectivity | Before and after amphetamine sensitization, Week 1, Week 5 | Functional connectivity between brain regions will be measured by means of magnet resonance imaging during a resting state of the subject. |
| Peripheral markers of sensitization | Baseline FDOPA scan, baseline PHNO + amphetamine scan, post-sensitization PHNO+ amphetamine scan, post-sensitization FDOPA scan, Time points: Week 1 Week 2 Week 4 | Plasma concentration of the dopamine metabolite HVA, glucose and insulin metabolism related parameters (glucose, glucagon, insulin, c-peptide, somatostatin), plasma cocaine and AMPH-regulated transcript (CART) levels will be measured at each PET study day. |
Countries
Austria
Contacts
Primary ContactAna Weidenauer, MD
Backup ContactMatthaeus Willeit, MD
Outcome results
None listed